Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate

NCT02491073 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT02491073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02491073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Observational
Overall status
Completed
Start date
September 30, 2015
Completion date
March 31, 2016
Enrollment
71 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy